Revise laws related to prior authorization
SB 447 revises Montana’s prior authorization rules for health insurance. The bill changes definitions in the state’s utilization review statutes and extends the default validity period for an approved certification from 3 months to 12 months. It also creates a special rule for chronic conditions: once a prior authorization is approved for treatment of a chronic condition, that authorization remains valid for the duration of the condition, and the insurer may not require the patient to reauthorize the same service again, though it may request proof that the condition still exists no more than once every 12 months.
The bill also limits when insurers may require prior authorization for certain prescriptions. It prohibits prior authorization in several situations, including some long-term generic prescriptions after six months of uninterrupted use, certain therapeutic-duplication scenarios where coverage was already approved, dosage adjustments within FDA-approved or clinically consistent ranges, certain long-acting injectable antipsychotics and related generic alternatives, medications for substance use disorder within labeled dosages, and at least one drug option in several pediatric and adult inhaler and insulin classes. If a prescription is denied during prior authorization, the insurer must provide a written notice listing reasonable therapeutic alternatives on the formulary, and adverse determinations must be made by a physician with relevant specialty expertise.
In terms of state law, SB 447 amends sections 33-32-102, 33-32-107, and 33-32-221 of the Montana Code Annotated, which govern health insurance utilization review and prior authorization. The bill is designed to reduce repeated authorization burdens, especially for chronic and ongoing treatment, and to make prescription coverage decisions more transparent and clinically grounded. It also includes coordination clauses to avoid conflicts with related bills if other legislation amending the same statutes is enacted.
The overall sentiment around the bill appears strongly favorable. It passed both chambers with large margins, including unanimous or near-unanimous votes in the House and final Senate concurrence, suggesting broad bipartisan support for easing prior authorization requirements and improving continuity of care. The absence of committee transcript material limits direct insight into debate, but the vote pattern indicates little organized opposition at the floor stage.
The main points of contention likely center on the balance between patient access and insurer utilization controls. Supporters would view the bill as reducing delays, administrative burden, and treatment interruptions for chronic illness, behavioral health, and common maintenance medications. Potential critics would be insurers and utilization review entities concerned that the new limits reduce their ability to manage costs, enforce medical necessity standards, or prevent inappropriate prescribing, particularly in the prescription-drug provisions.
SB 447 changes Montana insurance law by lengthening prior authorization approvals, creating a duration-of-condition rule for chronic care, and restricting insurer use of prior authorization for specified prescription drugs and drug classes. It directly amends the state’s utilization review and prior authorization statutes, affecting health insurance issuers, utilization review organizations, physicians, pharmacists, and covered persons enrolled in health plans. The bill is intended to streamline access to ongoing treatment and reduce repeated administrative review for patients with chronic or stable medication needs.
The bill’s legislative history shows strong support and little visible opposition. It advanced through the Senate and House with wide margins, including unanimous House concurrence and final Senate concurrence, indicating broad agreement that prior authorization should be limited in certain recurring or clinically stable situations. The vote pattern suggests the bill was viewed as a patient-access and administrative-reform measure rather than a controversial policy change.
The likely tension in SB 447 is between patient access and insurer management of care. Supporters favor fewer repeat authorizations, especially for chronic conditions, substance use disorder treatment, and common medications such as insulin and inhalers. Opponents, if any, would likely be insurers and utilization review organizations concerned that the bill narrows their ability to apply medical-necessity review, control costs, and respond to changing clinical circumstances. The bill’s requirement that adverse prescription denials be reviewed by a physician with the relevant specialty also reflects an effort to address concerns about non-specialist denials.